BCL2 and oropharyngeal carcinoma: A preclinical study of Obatoclax, a small molecule antagonist of the Bcl-2 family (B-cell lymphoma 2 (Bcl-2) is a downstream substrate of E6 that is associated with resistance to treatment [151]), indicates some therapeutic value in the treatment of oropharyngeal carcinoma [165].